Compare Huntington Ingalls Industries Inc (HII) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Ingalls Industries Inc vs Twist Bioscience Corp — how do they compare? Huntington Ingalls Industries Inc trades at $264.8 (market cap $10.44B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Huntington Ingalls Industries Inc and Twist Bioscience Corp are close in size by market cap, and Huntington Ingalls Industries Inc pays a 2.08% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Ingalls Industries Inc for 28 Days and Twist Bioscience Corp for 27 Days on average.
| HII | TWST | |
|---|---|---|
Market Cap | $10.44B | $10.08B |
Volume | 440,462 | 4,229,037 |
Sector | Industrials | Health |
52-Week High | $453.73 | $205.00 |
52-Week Low | $257.05 | $25.45 |
Typical Hold Time | 28 Days | 27 Days |
Enterprise Value | $13.37B | $10.01B |
Dividend Yield | 2.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HII trades at $265.02, up 1.67% today, with a bearish technical signal but strong fundamentals. The company reported consistent earnings beats, with Q2 2026 EPS of $5.27 surpassing expectations. Recent contract wins, including a $5.1 billion aircraft carrier overhaul, bolster revenue visibility from a $57.3 billion backlog. Valuation ratios appear reasonable with a P/E of 15.78 and P/S of 0.79.
The outlook is supported by robust defense budgets and contract momentum, but technical weakness and mixed analyst sentiment (40.7% buy, 55.6% hold) suggest near-term caution. Key risks include execution on large projects and defense spending cycles. The consensus price target of $363.67 implies significant upside if operational targets are met.
TWST trades at $152.05, down 2.31% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported Q2 2026 EPS of -$0.56, missing expectations, continuing a trend of losses despite revenue growth to $376.57M in 2025. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, driving investor optimism.
Outlook remains speculative with high valuation multiples (P/S 21.5, P/B 22.62) and persistent losses, but analyst consensus is bullish (73% buy ratings) with a $145.20 price target. Key risks include cash burn, competitive pressures, and reliance on AI-driven growth catalysts for profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
